Cannabics Pharmaceuticals Inc (OTCQB: CNBX), a company involved in personalised cannabinoid based cancer medicine, announced yesterday that it has named Itamar Borochov as its new director and member of its board.
Borochov is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies that operate in regulated markets. He was the original founder of Cannabics Pharmaceuticals Inc.
Eyal Barad, CEO and co-founder, said, 'The entire team is pleased to have Itamar return to the board at a very significant time, and I am sure his intimate knowledge and industry experience will significantly contribute to the company as we move into our next planned phases.'
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment
Privo Technologies doses first patient in first-in-human clinical trial of PRV131
Senhwa Biosciences signs clinical supply agreement with BeOne Medicines
Champions Oncology expands bioanalytical services with new technology and leadership
Poolbeg Pharma trial to feature in major CRS research programme
Natera acquires Foresight Diagnostics to expand MRD capabilities
OncoHost named Gold Winner in 2025 Merit Awards for Healthcare
Innovent Biologics and Takeda sign global strategic partnership
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Orano Med and Roche advance pretargeted radioimmunotherapy into clinical phase
OncoPrecision's ONC001 data selected for presentation at 67th ASH Annual Meeting and Exposition